John McCans

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

A comparison of recombinant Hirudin with Heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators

Synergy between publication and promotion: comparing adoption of new evidence in Canada and the United States

ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction

Acute Coronary Care in the Elderly, Part I

A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization

The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1

Mechanisms of Thrombus Formation

Use of Cardiac Procedures and Outcomes in Elderly Patients with Myocardial Infarction in the United States and Canada

Clopidogrel with or without Omeprazole in Coronary Artery Disease

Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety

Value of Acute Rest Sestamibi Perfusion Imaging for Evaluation of Patients Admitted to the Emergency Department With Chest Pain

Unstable angina: Pathogenesis, diagnosis, and treatment

Short- and long-term oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention

Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes

Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both

The Failing Heart — An Engine Out of Fuel

Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction

Rivaroxaban in Patients with a Recent Acute Coronary Syndrome

Aspirin, Heparin, and Fibrinolytic Therapy in Suspected Acute Myocardial Infarction

The Quality of Health Care Delivered to Adults in the United States

Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia

Drotrecogin Alfa (Activated) in Adults with Septic Shock

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

Intravenous nitroglycerin-induced heparin resistance: A qualitative antithrombin III abnormality

A new regimen for heparin use in acute coronary syndromes

New Antithrombotic Drugs

Platelet-Active Drugs

Low-Molecular-Weight Heparin (Fragmin) During Instability in Coronary Artery Disease (FRISC)

Irregular coronary lesion morphology after thrombolysis predicts early clinical instability

Effects of Prior Aspirin and Anti-Ischemic Therapy on Outcome of Patients With Unstable Angina 11This study was supported by Biogen, Inc., Cambridge, Massachusetts. Manuscript received July 28, 1997; revised manuscript received and accepted December 1, 1997.

Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris

Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

Unstable Angina Pectoris

Pathophysiology of acute coronary syndromes

Myocardial infarction patients in the 1990s—their risk factors, stratification and survival in Canada: The Canadian assessment of myocardial infarction (CAMI) study

Comparison of efficacy of low molecular weight heparin (parnaparin) with that of unfractionated heparin in the presence of activated platelets in healthy subjects

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes

Role of thrombosis in atherosclerosis and its complications

A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery Disease

Platelet Activation and Atherothrombosis

Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina

Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention

Antiplatelet Drugs

Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials

Unstable Angina: Good Long-Term Outcome After a Complicated Early Course

The Use of Aspirin in Ischemic Heart Disease

Usefulness of antithrombotic therapy in resting angina pectoris or non-Q-wave myocardial infarction in preventing death and myocardial infarction (a pilot study from the antithrombotic therapy in acute coronary syndromes study group)

Rates of Hyperkalemia after Publication of the Randomized Aldactone Evaluation Study

Design and Methodology of the PURSUIT Trial

The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes

Antithrombotic Therapy for Non–ST-Segment Elevation Acute Coronary Syndromes

Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era

Heparin and Low-Molecular-Weight Heparin

Intravenous heparin dosing

Aspirin and Mortality from Coronary Bypass Surgery

Prophylactic Heparin in Patients with Severe Sepsis Treated with Drotrecogin Alfa (Activated)

A dose-finding study of fondaparinux in patients with non–ST-segment elevation acute coronary syndromes

Guidelines for Percutaneous Coronary Interventions

Hospital Volume and Surgical Mortality in the United States

Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization fn1fn1This study was supported by Centocor, Inc., Malvern, Pennsylvania.

Incidence of Death and Acute Myocardial Infarction Associated With Stopping Clopidogrel After Acute Coronary Syndrome

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy

Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era

Comparison of Early Invasive and Conservative Strategies in Patients with Unstable Coronary Syndromes Treated with the Glycoprotein IIb/IIIa Inhibitor Tirofiban

Coronary lesion morphology in acute myocardial infarction: Demonstration of early remodeling after streptokinase treatment

Platelet Hyperreactivity and Prognosis in Survivors of Myocardial Infarction

The Determinants of Activated Partial Thromboplastin Time, Relation of Activated Partial Thromboplastin Time to Clinical Outcomes, and Optimal Dosing Regimens for Heparin Treated Patients with Acute Coronary Syndromes: A Review of GUSTO-IIb

A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease

The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes

Inflammation, Atherosclerosis, and Coronary Artery Disease

Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin

Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina

Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina

Percutaneous Transluminal Coronary Angioplasty

Reduction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin) in acute myocardial infarction

Hemorrhagic Complications of Anticoagulant Treatment

ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)

The Prognostic Value of C-Reactive Protein and Serum Amyloid A Protein in Severe Unstable Angina

A Comparison of Enoxaparin with Placebo for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

Hemorrhagic Complications of Anticoagulant Treatment

Effect of heparin, aspirin, or alteplase in reduction of myocardial ischaemia in refractory unstable angina

Antiplatelet agents for the treatment and prevention of atherothrombosis

Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis

Hemorrhagic Complications of Anticoagulant Treatment

Platelet-Active Drugs

Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

Variation among Hospitals in Coronary-Angiography Practices and Outcomes after Myocardial Infarction in a Large Health Maintenance Organization

The Tumor Necrosis Factor Ligand and Receptor Families

Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study

Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes

Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes

A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina

The Weight-based Heparin Dosing Nomogram Compared with a Standard Care Nomogram

Statewide Quality Improvement Initiatives and Mortality After Cardiac Surgery

Effect of Thromboxane A ₂ Blockade on Clinical Outcome and Restenosis After Successful Coronary Angioplasty

Antithrombotic therapy in cardiac disease. An emerging approach based on pathogenesis and risk.

Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators.

Comparison of Low-Molecular-Weight Heparin With Unfractionated Heparin Acutely and With Placebo for 6 Weeks in the Management of Unstable Coronary Artery Disease

Enoxaparin Prevents Death and Cardiac Ischemic Events in Unstable Angina/Non–Q-Wave Myocardial Infarction

Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome

ACC/AHA guidelines for coronary angiography11“ACC/AHA Guidelines for Coronary Angiography” was approved by the American College of Cardiology Board of Trustees in October 1998 and by the American Heart Association Science Advisory and Coordinating Committee in December 1998.22When citing this document, the American College of Cardiology and the American Heart Association request that the following format be used: Scanlon PJ, Faxon DP, Audet AM, Carabello B, Dehmer GJ, Eagle KA, Legako RD, Leon DF, Murray JA, Nissen SD, Pepine CJ, Watson RM. ACC/AHA guidelines for coronary angiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Coronary Angiography). J Am Coll Cardiol1999;33:1756–82433This document is available on the websites of the ACC (www.acc.org) and the AHA (www.americanheart.org). Reprints of this document (the complete guidelines) are available for $5 each by calling 800-253-4636 (US only) or writing the American College of Cardiology, Educational Services, 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint No. 71-0164. To obtain a reprint of the shorter version (executive summary and summary of recommendations) published in the May 4, 1999, issue of Circulation, ask for reprint No. 71-0163. To purchase additional reprints (specify version and reprint number): up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or e-mail pubauth@heart.org

Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes

Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation

American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy

Targeting G _βγ signaling in arterial vascular smooth muscle proliferation: A novel strategy to limit restenosis

Functional Arteries Grown in Vitro

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists

Diagnosing and managing unstable angina. Agency for Health Care Policy and Research.

Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction

Acute Coronary Syndromes

Aspirin and Other Platelet-Active Drugs

Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in nonprior aspirin users. Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease

Appropriate use of heparin. Empiric vs nomogram-based dosing.

Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association.

Unstable angina. A classification.

Remarks About Postinfarction Prognosis in Light of the Experience With the Gruppo Italiano per lo Studio della Sopravvivenza nell' Infarto Miocardico (GISSI) Trials

ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease

American Heart Association/American College of Cardiology Foundation guide to warfarin therapy11The American Heart Association makes every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This statement has been co-published in the April 1, 2003, issue of Circulation.This statement was approved by the American Heart Association Science Advisory and Coordinating Committee in October 2002 and by the American College of Cardiology Board of Trustees in February 2003. A single reprint is available by calling 800-242-8721 (US only) or writing the American Heart Association, Public Information, 7272 Greenville Ave, Dallas, TX 75231-4596. Ask for reprint No. 71-0254. To purchase additional reprints: up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 410-528-4426, fax 410-528-4264, or e-mail klbradle@lww.com. To make photocopies for personal or educational use, call the Copyright Clearance Center, 978-750-8400.

Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization

2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update)

Intracoronary Thrombus and Platelet Glycoprotein IIb/IIIa Receptor Blockade With Tirofiban in Unstable Angina or Non–Q-Wave Myocardial Infarction

Hemorrhagic Complications of Anticoagulant Treatment

Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical, biochemical, and angiographic correlates.

Role of Prostacyclin in the Cardiovascular Response to Thromboxane A ₂

A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes

Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism

Clinical Aspects of Platelet Inhibitors and Thrombus Formation

2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Coronary Plaque Disruption

Effects of an Angiotensin-Converting–Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients

Low-Molecular-Weight Heparins

Assessment of the Treatment Effect of Enoxaparin for Unstable Angina/Non–Q-Wave Myocardial Infarction

Preoperative Aspirin Therapy Is Associated With Improved Postoperative Outcomes in Patients Undergoing Coronary Artery Bypass Grafting

Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.

Hemorrhagic Complications of Anticoagulant Treatment

Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials.

Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease

Adding Heparin to Aspirin Reduces the Incidence of Myocardial Infarction and Death in Patients With Unstable Angina

Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide

The impact of training informal health care providers in India: A randomized controlled trial

Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty

2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes

Transient intermittent lymphocyte activation is responsible for the instability of angina.

Does More Intensive Treatment of Acute Myocardial Infarction in the Elderly Reduce Mortality?

Aspirin and other platelet active drugs. Relationship among dose, effectiveness, and side effects.

The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation

Oral Delivery of Anticoagulant Doses of Heparin

Prevention of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2-receptor blockade. A randomized, double-blind, placebo-controlled trial. Coronary Artery Restenosis Prevention on Repeated Thromboxane-Antagonism Study (CARPORT).

Reactivation of Unstable Angina after the Discontinuation of Heparin

Aspirin, Heparin, or Both to Treat Acute Unstable Angina

A Comparison of Management Patterns after Acute Myocardial Infarction in Canada and the United States

Activation of neurohumoral systems following acute myocardial infarction

Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina.